© Reuters. FILE PHOTO: Vials with a sticker reading, “COVID-19 / Coronavirus vaccine / Injection only” and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/File Photo
TORONTO (Reuters) – The Canadian province of Ontario will stop offering first doses of AstraZeneca (NASDAQ:)’s COVID-19 vaccine because of evidence that the risk of rare blood clots is somewhat higher than previously estimated, provincial officials said on Tuesday.
“This decision was made out of an abundance of caution due to an observed increase in the rare blood clotting known as vaccine-induced immune thrombotic thrombocytopenia,” said Chief Medical Officer David Williams (NYSE:).
“We are reviewing the data to consider options for the use of AstraZeneca for second doses and more broadly moving forward.”
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.